Literature DB >> 20383692

Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma.

Katjana Daskalow1, Nadine Rohwer, Esther Raskopf, Evelyne Dupuy, Anja Kühl, Christoph Loddenkemper, Bertram Wiedenmann, Volker Schmitz, Thorsten Cramer.   

Abstract

Hepatocellular carcinoma (HCC) is a hypervascularized tumor entity with association of arterial vessel density with poor prognosis. The hypoxia-inducible transcription factor HIF-1alpha represents a pivotal regulator of angiogenesis and is thought to determine the angiogenic nature of HCC. However, the precise role of HIF-1alpha during the pathogenesis of HCC remains elusive. We established a functional inactivation of HIF-1alpha in vitro and in vivo via RNAi and Cre/loxP-mediated recombination, respectively, to determine HIF-1alpha's role for tumor growth and chemosensitivity in transgenic and orthotopic murine HCC models. HIF-1alpha-deficient HCC cells displayed significantly reduced anchorage-independent growth and enhanced sensitivity toward etoposide, while basic cellular proliferation was unaffected. Analysis of gross tumor growth failed to detect reduced growth of HIF-1alpha-deficient tumors in the orthotopic and the transgenic HCC model, respectively. In line with the in vitro data, treatment of HIF-1alpha-deficient tumors with etoposide resulted in greater antiproliferative efficacy when compared to wild-type mice. Taken together, our study does not support a pivotal role of HIF-1alpha for tumor growth and angiogenesis in two murine HCC models. However, our data point toward a significant function of HIF-1alpha in determining chemosensitivity of HCC and therefore warrant validation of HIF-1alpha-inhibitors as adjuvant therapeutic agents in clinical studies of human HCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20383692     DOI: 10.1007/s00109-010-0623-4

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  45 in total

1.  HIF-1alpha is essential for myeloid cell-mediated inflammation.

Authors:  Thorsten Cramer; Yuji Yamanishi; Björn E Clausen; Irmgard Förster; Rafal Pawlinski; Nigel Mackman; Volker H Haase; Rudolf Jaenisch; Maripat Corr; Victor Nizet; Gary S Firestein; Hans Peter Gerber; Napoleone Ferrara; Randall S Johnson
Journal:  Cell       Date:  2003-03-07       Impact factor: 41.582

2.  Hypoxia protects HepG2 cells against etoposide-induced apoptosis via a HIF-1-independent pathway.

Authors:  Jean-Pascal Piret; Jean-Philippe Cosse; Noelle Ninane; Martine Raes; Carine Michiels
Journal:  Exp Cell Res       Date:  2006-06-07       Impact factor: 3.905

3.  Hypoxia-inducible factor 1alpha mediates anoikis resistance via suppression of alpha5 integrin.

Authors:  Nadine Rohwer; Martina Welzel; Katjana Daskalow; David Pfander; Bertram Wiedenmann; Katharina Detjen; Thorsten Cramer
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

Review 4.  Hypoxia-inducible factor 1 (HIF-1) pathway.

Authors:  Gregg L Semenza
Journal:  Sci STKE       Date:  2007-10-09

5.  Hypoxia-inducible expression of the mouse carbonic anhydrase IX demonstrated by new monoclonal antibodies.

Authors:  Martina Takacova; Monika Barathova; Alzbeta Hulikova; Anna Ohradanova; Juraj Kopacek; Seppo Parkkila; Jaromir Pastorek; Silvia Pastorekova; Miriam Zatovicova
Journal:  Int J Oncol       Date:  2007-11       Impact factor: 5.650

6.  Tumoral angiogenesis and tissue factor expression during hepatocellular carcinoma progression in a transgenic mouse model.

Authors:  Evelyne Dupuy; Patricia Hainaud; Aude Villemain; Eva Bodevin-Phèdre; Jean Philippe Brouland; Pascale Briand; Gérard Tobelem
Journal:  J Hepatol       Date:  2003-06       Impact factor: 25.083

7.  siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo.

Authors:  Esther Raskopf; Annabelle Vogt; Tilman Sauerbruch; Volker Schmitz
Journal:  J Hepatol       Date:  2008-09-21       Impact factor: 25.083

Review 8.  Systemic therapy of hepatocellular carcinoma: are we making progress?

Authors:  Patricia Roxburgh; T R Jeffry Evans
Journal:  Adv Ther       Date:  2008-11       Impact factor: 3.845

9.  Systemic therapy for hepatocellular carcinoma.

Authors:  Melanie B Thomas
Journal:  Cancer J       Date:  2008 Mar-Apr       Impact factor: 3.360

10.  A novel quasi-viral agent, MaTu, is a two-component system.

Authors:  S Pastoreková; Z Závadová; M Kostál; O Babusíková; J Závada
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

View more
  14 in total

1.  Development of a novel score for early detection of hepatocellular carcinoma among high-risk hepatitis C virus patients.

Authors:  Hatem A El-mezayen; Hossam Darwish
Journal:  Tumour Biol       Date:  2014-04-01

Review 2.  Hypoxia and hypoxia inducible factors: diverse roles in liver diseases.

Authors:  Bharath Nath; Gyongyi Szabo
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

3.  Stabilization but No Functional Influence of HIF-1α Expression in the Intestinal Epithelium during Salmonella Typhimurium Infection.

Authors:  Laura Robrahn; Aline Dupont; Sandra Jumpertz; Kaiyi Zhang; Christian H Holland; Joël Guillaume; Sabrina Rappold; Johanna Roth; Vuk Cerovic; Julio Saez-Rodriguez; Mathias W Hornef; Thorsten Cramer
Journal:  Infect Immun       Date:  2022-01-03       Impact factor: 3.609

4.  Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429.

Authors:  Cheng-Jun Sui; Yan-Ming Zhou; Wei-Feng Shen; Bing-Hua Dai; Jiong-Jiong Lu; Min-Feng Zhang; Jia-Mei Yang
Journal:  J Mol Med (Berl)       Date:  2016-07-05       Impact factor: 4.599

5.  Hypoxia-inducible factor 1, hepatocellular carcinoma and angiogenesis.

Authors:  Jin-Wook Kim
Journal:  Korean J Hepatol       Date:  2010-09

Review 6.  Hypoxia inducible factors in hepatocellular carcinoma.

Authors:  Chu Chen; Tao Lou
Journal:  Oncotarget       Date:  2017-07-11

7.  Annexin A1 sustains tumor metabolism and cellular proliferation upon stable loss of HIF1A.

Authors:  Nadine Rohwer; Fabian Bindel; Christina Grimm; Suling J Lin; Jessica Wappler; Bertram Klinger; Nils Blüthgen; Ilona Du Bois; Bernd Schmeck; Hans Lehrach; Marjo de Graauw; Emanuel Goncalves; Julio Saez-Rodriguez; Patrick Tan; Heike I Grabsch; Alessandro Prigione; Stefan Kempa; Thorsten Cramer
Journal:  Oncotarget       Date:  2016-02-09

8.  WWOX controls hepatic HIF1α to suppress hepatocyte proliferation and neoplasia.

Authors:  Muhannad Abu-Remaileh; Abed Khalaileh; Eli Pikarsky; Rami I Aqeilan
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

9.  Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH.

Authors:  Davide Povero; Hirokazu Yamashita; Wenhua Ren; Mani G Subramanian; Robert P Myers; Akiko Eguchi; Douglas A Simonetto; Zachary D Goodman; Stephen A Harrison; Arun J Sanyal; Jaime Bosch; Ariel E Feldstein
Journal:  Hepatol Commun       Date:  2020-07-03

Review 10.  Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma.

Authors:  Misu Lee; Haeyong Ko; Mijin Yun
Journal:  Yonsei Med J       Date:  2018-12       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.